brentuximab vedotin
seagen,takeda
['lymsm', 'lymphoma']
congress #asco22 | stephen ansell reports on 6 year follow-up of the echelon-1 trial of pts with stage iii/ iv chl of a+avd vs abvd. os favored a+avd vs abvd (p = 0.009). estimated 6-year os rates were 93.9% vs 89.4% with a+avd vs abvd, respectively. #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm